Nootropic & Neuroprotective Research · COA Verified
For research and laboratory use only. Not for human consumption. By purchasing, you confirm you are a qualified researcher.
For Research Purposes Only. Not approved for human consumption.
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) originally developed in Russia based on the adrenocorticotropic hormone (ACTH) fragment 4-10. Unlike ACTH, Semax lacks hormonal activity but retains potent neuroprotective and cognitive-enhancing properties in research models. It has been extensively studied for effects on brain-derived neurotrophic factor (BDNF), serotonin metabolism, and cerebral blood flow. Semax does not bind to classic monoamine receptors, instead working through gene expression changes and neurotrophic factor regulation.
Q: How does Semax work in research models?
A: Increases BDNF expression, modulates serotonin turnover, enhances cerebral blood flow, and alters expression of genes involved in immune regulation and neuroprotection. Does not bind monoamine receptors directly.
Q: What is BDNF and why does it matter?
A: Brain-Derived Neurotrophic Factor is a neurotrophin essential for neuronal survival, synaptic plasticity, and long-term memory formation. Semax research shows significant BDNF upregulation.
Q: How does Semax differ from ACTH?
A: Semax is derived from ACTH 4-10 but lacks the corticotropic activity. It retains neuroprotective properties without stimulating adrenal steroidogenesis.
Related Research: Selank Research Peptide | NAD+ Neuroprotection
For laboratory research use only. Not for human consumption. Not evaluated by the FDA.
